Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Tolerance and Acceptability of Rasagiline in the Treatment of Early-stage Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* male or female aged between 18 and 70~* capable of reading and understanding the information leaflet given to him/her~* signed an inform consent form~* presenting with idiopathic Parkinson's disease with a Hoehn and Yahr score of ≤ 3~* has never been given anti-Parkinson medication, or has been treated with L-Dopa, on condition that the total duration of treatment was less than twelve weeks at a dosage of under 200 mg, or has been treated with a dopamine agonist other than Pramipexole, on condition that:~  * either the patient is still in the dose-titration phase at the time of inclusion~ * or that the treatment was administered for less than six weeks and was completed two weeks before inclusion~Exclusion Criteria:~* women who are pregnant, breastfeeding, or planning a pregnancy in the months after joining the study~* women of reproductive age who have not undergone surgical sterilisation or who are not using a reliable method of contraception before joining the study and during the study~* patient presenting with hepatic insufficiency~* patient presenting with a concommitant illness which is considered significant by the investigator, after examination of the history, the patient's clinical condition, or on the basis on any additional examinations performed~* patient presenting with a skin lesion considered to be suspect by the investigator and which has not been evaluated by a dermatologist~* patient presenting with a contraindication to treatment with Rasagiline or Pramipexole (please see the SPC for the respective products)~* patient treated with fuoxetine during the five weeks preceding inclusion~* patient treated with fluvoxamine, pethidine, selegiline or any other MAOI during the two weeks preceding inclusion~* patient who has had deep brain stimulation treatment~* patient who might receive dextromethorphan or a sympathomimetic during the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Rasagiline (Type: EXPERIMENTAL): None
- Pramipexole (Type: ACTIVE_COMPARATOR): pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)

Based on this trial design, predict the completion outcome and termination type (if applicable).